Residency · Residency · Cardiothoracic Surgery

Aortic Pathology in Connective Tissue Disorders

Overview

Heritable connective tissue disorders represent a critical subset of aortic disease requiring specialized management. These patients present earlier in life, have more aggressive aortic pathology, and require lifelong surveillance. The key syndromes include Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, Turner syndrome, and familial thoracic aortic aneurysm and dissection (FTAAD). Genetic testing and family screening are integral components of management.

Marfan Syndrome

Genetics and Pathophysiology

Marfan syndrome is caused by an autosomal dominant mutation in the FBN1 gene encoding fibrillin-1, with a prevalence of approximately 1 in 5,000. Defective fibrillin leads to impaired microfibril assembly and excessive TGF-beta signaling, resulting in cystic medial degeneration characterized by elastic fiber fragmentation, smooth muscle cell loss, and mucoid accumulation. Aortic root dilatation is the hallmark cardiovascular manifestation.

Cardiovascular Manifestations

Aortic root aneurysm (dilatation of the sinuses of Valsalva) is the most common cause of morbidity and mortality. Aortic dissection occurs more frequently in the ascending aorta (Type A) than the descending aorta. Mitral valve prolapse with regurgitation is present in 60-80% of patients. Pulmonary artery dilatation occurs but is rarely clinically significant.

Surgical Indications for Aortic Intervention

ACC/AHA guidelines recommend intervention when the aortic root diameter reaches 5.0 cm or greater. A root diameter of 4.5 cm or greater warrants surgery in the presence of a family history of aortic dissection, rate of growth exceeding 0.5 cm per year, severe aortic regurgitation, or desire for pregnancy. A root diameter of 4.0 cm or greater triggers intervention at the time of another cardiac surgery.

Surgical Options

A composite valve-graft (Bentall) with a mechanical valve and tube graft provides durability but requires lifelong anticoagulation. Valve-sparing root replacement (David reimplantation) is preferred when valve morphology is suitable, as it preserves the native valve and avoids anticoagulation; it has shown excellent long-term results in experienced centers but requires favorable cusp morphology without significant prolapse or calcification. The Ross procedure is generally contraindicated in Marfan syndrome due to the risk of neoaortic root dilatation.

<image>Comparison of Bentall composite valve-graft and David valve-sparing root replacement techniques for Marfan aortic root aneurysm</image>

Loeys-Dietz Syndrome

Genetics and Classification

Loeys-Dietz syndrome (LDS) is caused by autosomal dominant mutations in TGF-beta signaling pathway genes. Five types are recognized: LDS Type 1 (TGFBR1), Type 2 (TGFBR2), Type 3 (SMAD3), Type 4 (TGFB2), and Type 5 (TGFB3). LDS produces more aggressive aortic disease than Marfan syndrome, with dissection occurring at smaller diameters.

Clinical Features

Characteristic craniofacial features include hypertelorism, bifid uvula, and cleft palate. Arterial tortuosity is present throughout the vascular tree. Unlike Marfan syndrome, aneurysms extend beyond the aortic root to involve the arch, descending aorta, and branch vessels (carotid, vertebral, splenic). Cervical spine instability is an additional concern. Widespread arterial aneurysms and dissections occur at younger ages.

Surgical Management

The intervention threshold is earlier than in Marfan syndrome: 4.0-4.2 cm for the aortic root (compared to 5.0 cm in Marfan). More aggressive downstream aortic surveillance is required due to the diffuse arteriopathy. Valve-sparing root replacement is preferred when feasible. Tissue fragility is a significant operative concern, and pledgeted sutures are recommended. Serial imaging of the entire arterial tree is essential.

<image>Loeys-Dietz syndrome arterial tortuosity on CT angiography showing characteristic tortuous and aneurysmal cerebral and visceral vessels</image>

Vascular Ehlers-Danlos Syndrome (Type IV)

Genetics and Pathophysiology

Vascular Ehlers-Danlos syndrome is caused by an autosomal dominant mutation in the COL3A1 gene encoding type III procollagen. It is the most dangerous EDS subtype for vascular complications, with a median survival of approximately 50 years without intervention. Extreme tissue fragility affects arteries, intestines, and uterus, all of which are prone to spontaneous rupture.

Clinical Features

Patients have thin, translucent skin with visible veins, easy bruising, and characteristic facial features (thin lips, narrow nose, hollow cheeks). Arterial rupture often occurs without a preceding aneurysm. Intestinal and uterine rupture are additional concerns. Unlike classical EDS, musculoskeletal features are minimal or absent.

Surgical Considerations

Surgery is extremely high-risk due to tissue fragility. Operative management is reserved for life-threatening complications such as active rupture, and conservative management is preferred whenever possible. Endovascular approaches carry significant access site complication risk. Sutures cut through tissue readily, making pledgets, felt reinforcement, and gentle tissue handling mandatory. Celiprolol, a beta-blocker, has been shown in a randomized trial to reduce vascular events.

Turner Syndrome

Cardiovascular Pathology

Turner syndrome (45,X karyotype) affects approximately 1 in 2,500 live female births. Cardiovascular manifestations include bicuspid aortic valve in 15-30%, aortic coarctation in 7-18%, and aortic dilatation with dissection risk that is disproportionate to body size. The aortic size index (ASI) is used for risk stratification, with ASI exceeding 2.5 cm/m2 indicating increased risk.

Surgical Management

Standard population aortic diameter thresholds are not appropriate for Turner syndrome patients due to their small body size; the aortic size index rather than absolute diameter should guide decisions. Intervention is recommended when ASI exceeds 2.5 cm/m2 or the absolute diameter exceeds 4.0 cm. The risk of dissection is higher during pregnancy, making preconception aortic assessment mandatory. Bicuspid valve management follows standard guidelines but with closer surveillance.

<image>Echocardiographic parasternal long-axis view demonstrating aortic root dilatation at the sinuses of Valsalva in a patient with Marfan syndrome</image>

Familial Thoracic Aortic Aneurysm and Dissection (FTAAD)

Overview

FTAAD represents non-syndromic heritable thoracic aortic disease, accounting for approximately 20% of thoracic aortic aneurysms. Multiple genes have been identified, including ACTA2, MYH11, SMAD3, MYLK, PRKG1, and LOX, among others. Inheritance is autosomal dominant with variable penetrance and expressivity.

Key Gene-Specific Considerations

ACTA2 mutations are associated with livedo reticularis, iris flocculi, premature coronary artery disease, and Moyamoya disease. MYH11 mutations are associated with patent ductus arteriosus. PRKG1 mutations produce particularly aggressive disease with dissection at normal aortic diameters. Surgical thresholds vary by gene, making genetic counseling and gene-specific guidelines important.

Connective Tissue Disorders Comparison

Medical Management Across All Syndromes

Beta-blockers are the cornerstone of therapy, reducing aortic wall stress by decreasing dP/dt. Losartan (an ARB) targets the TGF-beta pathway and has been studied in Marfan syndrome; despite conflicting trial results, it is widely used. Blood pressure control targets less than 120/80 mmHg. Activity restrictions include avoidance of isometric exercise, contact sports, and competitive athletics. Fluoroquinolones should be avoided due to their association with aortic aneurysm and dissection risk. Pregnancy counseling is essential, requiring high-risk obstetric management with a multidisciplinary team.

Surveillance Protocols

Annual echocardiography or MRA is recommended for stable aortic dimensions, with more frequent imaging (every 6 months) when approaching the surgical threshold or showing growth. Full aortic imaging (CT or MRA from root to bifurcation) should be obtained at baseline and periodically. First-degree relative screening with echocardiography and/or genetic testing is essential. Transition planning for adolescent patients moving to adult care should be formalized.

<image>Algorithm for surgical decision-making in connective tissue disorders showing gene-specific aortic diameter thresholds for intervention</image>

Clinical Pearls

Standard population aortic diameter thresholds should never be applied to connective tissue disorder patients — they dissect at smaller sizes. Loeys-Dietz syndrome is more aggressive than Marfan, warranting intervention at 4.0-4.2 cm rather than 5.0 cm. Vascular EDS is a surgical minefield — elective surgery should be avoided, and tissues must be handled with extreme care when operating. Valve-sparing root replacement is the gold standard in Marfan syndrome when cusp morphology permits. The entire aorta should always be imaged, not just the root, because downstream disease is common, especially in LDS. Genetic testing informs surgical thresholds, family screening, and reproductive counseling. Pregnancy in these patients requires preconception cardiovascular assessment and multidisciplinary high-risk obstetric care.

References

• Hiratzka LF et al. "2010 ACC/AHA Guidelines for Thoracic Aortic Disease." Circulation. 2010.
• Isselbacher EM et al. "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease." Circulation. 2022.
• Loeys BL et al. "Loeys-Dietz syndrome." GeneReviews. Updated 2023.
• David TE et al. "Long-term results of aortic valve-sparing operations in patients with Marfan syndrome." J Thorac Cardiovasc Surg. 2015.
• Ong KT et al. "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome." Lancet. 2010.
• Lacro RV et al. "Atenolol vs losartan in Marfan syndrome (pediatric)." N Engl J Med. 2014.

Read this lecture as Markdown